financetom
Business
financetom
/
Business
/
Yes Bank scam: Wadhawan brothers' plea for FIR copy rejected
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Yes Bank scam: Wadhawan brothers' plea for FIR copy rejected
Apr 17, 2020 6:54 AM

A special court here has rejected the plea of DHFL promoter Kapil Wadhawan and his brother Dheeraj, seeking inspection and certified copies of the FIR registered against them in connection with the Yes Bank scam.

The plea was rejected by the court on the grounds that the matter is not urgent and the accused has liberty to apply after the lockdown is lifted, Wadhawans' lawyer said on Friday.

The Wadhawan brothers are named as accused in the Central Bureau of Investigation (CBI) FIR pertaining to the swindling of money by Yes Bank promoter Rana Kapoor and others.

Both Kapil and Dheeraj were absconding since the case was registered against them on March 7, prompting the CBI to get non-bailable warrants (NBWs) against them from a special court.

The agency has alleged that Kapoor, 62, entered into a criminal conspiracy with the Wadhawans for extending the financial assistance to DHFL through Yes Bank in return of substantial undue benefits to himself and his family members through companies held by them.

According to the CBI FIR, the scam started taking shape between April and June 2018 when Yes Bank invested Rs 3,700 crore in short-term debentures of the scam-hit Dewan Housing Finance Corporation Ltd (DHFL).

In return, the Wadhawans allegedly "paid kickback of Rs 600 crore" to Kapoor and his family members in the form of loan to DoIT Urban Ventures (India) Pvt Ltd, a firm linked to the Kapoor family, the agency has said.

The CBI's FIR came after the Enforcement Directorate (ED) arrested Kapoor in connection with the scam last month. He is currently in judicial custody. .

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Nutrien Considers Divestments, Management Changes in South American Operations
Market Chatter: Nutrien Considers Divestments, Management Changes in South American Operations
Mar 28, 2024
02:33 PM EDT, 03/28/2024 (MT Newswires) -- Nutrien ( NTR ) is considering strategic changes in South America over significant losses in the region including divestments, new management and stopping its acquisition spree in Brazil, Reuters reported Thursday, citing sources with direct knowledge of the matter. The company has already separated Brazil from the rest of its regional operations and...
CANADA ECONOMICS FEATURE: CIBC's Avery Shenfeld On the Productivity Malaise
CANADA ECONOMICS FEATURE: CIBC's Avery Shenfeld On the Productivity Malaise
Mar 28, 2024
02:33 PM EDT, 03/28/2024 (MT Newswires) -- Avery Shenfeld noted Thursday this week's speech by the Bank of Canada's Carolyn Rogers drew useful attention to the symptoms of Canada's productivity malaise. But, he said, we're still left without much progress towards a diagnosis, the first step towards a cure, and that might explain why public policy efforts in this area...
Kitchen sponge maker Scrub Daddy explores sale, sources say
Kitchen sponge maker Scrub Daddy explores sale, sources say
Mar 28, 2024
March 28 (Reuters) - Scrub Daddy, the kitchen sponge maker that gained popularity after securing an investment on U.S. TV show Shark Tank, is exploring options that include a sale of the company, according to people familiar with the matter. Scrub Daddy, which is backed by entrepreneur Lori Greiner, has hired JPMorgan Chase ( JPM ) to advise on whether...
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis
Mar 28, 2024
02:32 PM EDT, 03/28/2024 (MT Newswires) -- 4D Molecular Therapeutics ( FDMT ) said it conducted initial pivotal study interactions with the US Food and Drug Administration and European Medicines Agency over its development plans for 4D-710 for treatment of cystic fibrosis lung disease. We are encouraged by our productive interactions with the FDA and EMA, said CEO David Kirn....
Copyright 2023-2026 - www.financetom.com All Rights Reserved